Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
EPS (Diluted)
Nektar Therapeutics
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
EPS (Diluted)
$0
|
CAGR 3-Years
33%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-7%
|
||
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$5
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
||
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$0
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-8%
|
||
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$4
|
CAGR 3-Years
19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
||
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$9
|
CAGR 3-Years
12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
14%
|
Nektar Therapeutics
Glance View
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
See Also
What is Nektar Therapeutics's EPS (Diluted)?
EPS (Diluted)
-0.8
USD
Based on the financial report for Sep 30, 2024, Nektar Therapeutics's EPS (Diluted) amounts to -0.8 USD.
What is Nektar Therapeutics's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-7%
Over the last year, the EPS (Diluted) growth was 49%. The average annual EPS (Diluted) growth rates for Nektar Therapeutics have been 33% over the past three years , 20% over the past five years , and -7% over the past ten years .